Education

1989-1995 University of California, Los Angeles, PhD

1984-1987 Shanghai Second Medical University, Master's degree

1980-1984 Wuhan University, Bachelor's degree

 

Academic Experience

2016-present Peking University Boya Chair Professor

2013-present  Director, Peking University Stem Cell Research Center

2011-present  Senior Researcher, Peking University-Tsinghua Life Science Center

2001-present  Professor, Chang Jiang Scholars Program, Peking University

1998-2001      Director of Molecular Biology, Viacell Inc., Massachusetts, USA

1997-1998      Director of Department of Immunobiology,  Antigen Express, Inc., Massachusetts, USA

1995-1997      Postdoctoral research, Skirball Institute, New York University Medical Center

Overview of Academic Research

Research Fields: somatic reprogramming, cell fate regulation, stem cell and regenerative medicine application

 

1.  Established the new technology: chemical reprogramming and discovered the molecular mechanism

2.  The first case in the world of CRISPR editing stem cells to treat HIV and leukemia patients

3.  Established a new treatment scheme of CAR-T cells combined with innate immune cells

4.  Achieved long-term maintenance of mature liver cell function and fate in vitro

5.  Established pluripotent stem cells with embryonic and extraembryonic potency

6.  Discovered a new model for regulating the fate of pluripotent stem cells

Major Honor and Awards

Prominent Achievement Award of WuXi AppTec Life Chemistry Research (2013)

The 7th "Tan Jiazhen Life Science Award" (2014)

The 18th Wu Jieping-Paul Janssen Medical Pharmaceutical Award (2017)

Outstanding Contribution Award of Stem Cells at the China Stem Cell Annual Conference (2018)

Outstanding Achievement Award of China Society of Cell Biology (2019)

Peking University Guohua Outstanding Scholar Award (2019)

Selected as the top ten scientific figures of Nature in 2019

Chief scientist of 973 project and national key research and development plan

Representative Research Achievements

Hou, P., Li, Y., Zhang, X., Liu, C., Guan, J., Li, H., Zhao, T., Ye, J., Yang, W., and Liu, K. (2013). Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341, 651-654.

 

Shu, J., Wu, C., Wu, Y., Li, Z., Shao, S., Zhao, W., Tang, X., Yang, H., Shen, L., and Zuo, X. (2013). Induction of pluripotency in mouse somatic cells with lineage specifiers. Cell 153, 963-975.

 

Zhao, Y., Zhao, T., Guan, J., Zhang, X., Fu, Y., Ye, J., Zhu, J., Meng, G., Ge, J., and Yang, S. (2015). A XEN-like state bridges somatic cells to pluripotency during chemical reprogramming. Cell 163, 1678-1691.

 

Yang, Y., Liu, B., Xu, J., Wang, J., Wu, J., Shi, C., Xu, Y., Dong, J., Wang, C., and Lai, W. (2017). Derivation of pluripotent stem cells with in vivo embryonic and extraembryonic potency. Cell 169, 243-257. e225.

 

Zhao, T., Fu, Y., Zhu, J., Liu, Y., Zhang, Q., Yi, Z., Chen, S., Jiao, Z., Xu, X., and Xu, J. (2018). Single-cell RNA-seq reveals dynamic early embryonic-like programs during chemical reprogramming. Cell stem cell 23, 31-45. e37.

 

Xiang, C., Du, Y., Meng, G., Soon Yi, L., Sun, S., Song, N., Zhang, X., Xiao, Y., Wang, J., and Yi, Z. (2019). Long-term functional maintenance of primary human hepatocytes in vitro. Science 364, 399-402.

 

Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., and Zhang, B. (2019). CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. New England Journal of Medicine 381, 1240-1247.

 

Guan, J., Wang, G., Wang, J., Zhang, Z., Fu, Y., Cheng, L., Meng, G., Lyu, Y., Zhu, J., and Li, Y. (2022). Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature 605, 325-331.

 

Du, Y., Liang, Z., Wang, S., Sun, D., Wang, X., Liew, S.Y., Lu, S., Wu, S., Jiang, Y., and Wang, Y. (2022). Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nature Medicine 28, 272-282.